Literature DB >> 28895545

Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination?

Marc Niebel1, Joshua B Singer1, Sema Nickbakhsh1, Robert J Gifford1, Emma C Thomson2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28895545     DOI： 10.1016/S2468-1253(17)30257-1

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


× No keyword cloud information.
  10 in total

1.  Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences.

Authors:  Anna L McNaughton; Peter A Revill; Margaret Littlejohn; Philippa C Matthews; M Azim Ansari
Journal:  J Gen Virol       Date:  2020-03       Impact factor: 3.891

Review 2.  Epidemiology of hepatitis B, C and D in Malawi: systematic review.

Authors:  Alexander J Stockdale; Collins Mitambo; Dean Everett; Anna Maria Geretti; Melita A Gordon
Journal:  BMC Infect Dis       Date:  2018-10-12       Impact factor: 3.090

3.  GLUE: a flexible software system for virus sequence data.

Authors:  Joshua B Singer; Emma C Thomson; John McLauchlan; Joseph Hughes; Robert J Gifford
Journal:  BMC Bioinformatics       Date:  2018-12-18       Impact factor: 3.169

Review 4.  Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.

Authors:  Anna L McNaughton; Valentina D'Arienzo; M Azim Ansari; Sheila F Lumley; Margaret Littlejohn; Peter Revill; Jane A McKeating; Philippa C Matthews
Journal:  Gastroenterology       Date:  2018-09-27       Impact factor: 22.682

Review 5.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883

6.  Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments.

Authors:  Chris Davis; George S Mgomella; Ana da Silva Filipe; Eric H Frost; Genevieve Giroux; Joseph Hughes; Catherine Hogan; Pontiano Kaleebu; Gershim Asiki; John McLauchlan; Marc Niebel; Ponsiano Ocama; Cristina Pomila; Oliver G Pybus; Jacques Pépin; Peter Simmonds; Joshua B Singer; Vattipally B Sreenu; Clara Wekesa; Elizabeth H Young; Donald G Murphy; Manj Sandhu; Emma C Thomson
Journal:  Hepatology       Date:  2019-03-22       Impact factor: 17.425

7.  Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study.

Authors:  Cas J Isfordink; Thijs J W van de Laar; Sjoerd P H Rebers; Els Wessels; Richard Molenkamp; Marjolein Knoester; Bert C Baak; Cees van Nieuwkoop; Bart van Hoek; Sylvia M Brakenhoff; Hans Blokzijl; Joop E Arends; Marc van der Valk; Janke Schinkel
Journal:  Open Forum Infect Dis       Date:  2021-01-06       Impact factor: 3.835

Review 8.  Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.

Authors:  Rajiv Shah; Lucrece Ahovegbe; Marc Niebel; James Shepherd; Emma C Thomson
Journal:  J Hepatol       Date:  2021-05-08       Impact factor: 25.083

9.  Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.

Authors:  Elihu Aranday-Cortes; C Patrick McClure; Christopher Davis; William L Irving; Kazeem Adeboyejo; Lily Tong; Ana da Silva Filipe; Vattipally Sreenu; Kosh Agarwal; David Mutimer; Benjamin Stone; Matthew E Cramp; Emma C Thomson; Jonathan K Ball; John McLauchlan
Journal:  J Infect Dis       Date:  2022-09-21       Impact factor: 7.759

10.  Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.

Authors:  Juan Li; Dong-Bo Wu; Wei Jiang; Xue-Bin Chen; Gui-Bao Xiao; Yong-Hong Wang; Meng-Lan Wang; Ya-Chao Tao; En-Qiang Chen
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.